Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Create alerts with multiple filters including highs/low, comparative values, and turning points. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,589,396
  • Shares Outstanding, K 70,037
  • Annual Sales, $ 351,410 K
  • Annual Income, $ -454,030 K
  • 60-Month Beta 1.21
  • Price/Sales 10.40
  • Price/Cash Flow N/A
  • Price/Book 5.39
Trade RARE with:

Options Overview Details

View History
  • Implied Volatility 54.91% ( -5.90%)
  • Historical Volatility 60.63%
  • IV Percentile 20%
  • IV Rank 27.39%
  • IV High 92.52% on 07/11/22
  • IV Low 40.73% on 01/14/22
  • Put/Call Vol Ratio 0.67
  • Today's Volume 20
  • Volume Avg (30-Day) 279
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 8,373
  • Open Int (30-Day) 7,318

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -1.49
  • Number of Estimates 11
  • High Estimate 4.84
  • Low Estimate -3.04
  • Prior Year -1.08
  • Growth Rate Est. (year over year) -37.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.10 +5.03%
on 07/19/22
68.68 -24.91%
on 07/13/22
-14.29 (-21.70%)
since 07/12/22
3-Month
45.20 +14.09%
on 05/25/22
68.68 -24.91%
on 07/13/22
+1.15 (+2.28%)
since 05/12/22
52-Week
45.20 +14.09%
on 05/25/22
104.38 -50.59%
on 09/07/21
-41.14 (-44.37%)
since 08/12/21

Most Recent Stories

More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 51.57 (+0.62%)
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

RARE : 51.57 (+0.62%)
ABEO : 4.43 (-4.94%)
SRRK : 11.30 (+10.57%)
BNTX : 160.35 (+1.11%)
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RARE : 51.57 (+0.62%)
ANIP : 37.47 (+5.88%)
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

Second quarter 2022 total revenue of $89.3 million and Crysvita® revenue in Ultragenyx territories1 of $64.0 million Reaffirm 2022 Crysvita revenue in...

RARE : 51.57 (+0.62%)
Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update

NOVATO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 51.57 (+0.62%)
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RARE : 51.57 (+0.62%)
ALNY : 233.85 (+1.94%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 51.57 (+0.62%)
Why Ultragenyx Pharmaceutical Stock Is Cratering Today

Shareholders aren't happy with the biotech's decision to acquire an early-stage asset for Angelman syndrome.

RARE : 51.57 (+0.62%)
Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

BEAM : 69.08 (+4.52%)
ANIK : 22.38 (+2.94%)
RARE : 51.57 (+0.62%)
FATE : 33.82 (+3.58%)
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

Doses up to 10 mg show good tolerability and meaningful clinical activity in multiple domains U.K. and Canadian health authorities approved escalation to...

RARE : 51.57 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 53.67
2nd Resistance Point 53.01
1st Resistance Point 52.29
Last Price 51.57
1st Support Level 50.92
2nd Support Level 50.26
3rd Support Level 49.54

See More

52-Week High 104.38
Fibonacci 61.8% 81.77
Fibonacci 50% 74.79
Fibonacci 38.2% 67.81
Last Price 51.57
52-Week Low 45.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar